Efficacy of voriconazole in treatment of murine pulmonary blastomycosis.
We evaluated the efficacy of voriconazole, a new broad-spectrum triazole antifungal compound, in the treatment of murine pulmonary blastomycosis. Since mice metabolize voriconazole rapidly, we took advantage of our previous observation that administration of grapefruit juice to mice resulted in suitable serum voriconazole concentrations so that treatment studies with mice could be done (A. M. Sugar and X.-P. Liu, Med. Mycol. 38:209-121, 2000). Our results show that voriconazole prolonged survival in a dose-dependent fashion and that the fungal burden in the lungs was decreased by voriconazole administered at 40 mg/kg of body weight/day. Voriconazole should be studied in humans with blastomycosis.
Sugar
A M
AM
Evans Memorial Department of Clinical Research and Department of Medicine, Boston Medical Center, Boston, Massachusetts 02118, USA. asugar@medicine.bu.edu
Liu
X P
XP
D000818:Animals; D000935:Antifungal Agents / Q000097:blood / Q000627:therapeutic use*; D001759:Blastomycosis / Q000188:drug therapy* / Q000382:microbiology; D015169:Colony Count, Microbial; D008168:Lung / Q000382:microbiology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011743:Pyrimidines / Q000097:blood / Q000627:therapeutic use*; D016019:Survival Analysis; D013997:Time Factors; D014230:Triazoles / Q000097:blood / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole